Available Technologies

ADDITIONAL FILTERS

295 available technologies

Trypterygium Wilfordii II Hook F Extracts as Therapeutic Agents

The present invention provides for the use of Tripterygium wilfordii Hook F extracts and purified components thereof in the treatment of inflammation or an immune disorder with concomitant lack of steroidal effect. Extracts of this plant (T2) bound to the glucocorticoid receptor and competitively inhibited glucocorticoid mediated cellular processes, such as dexamethasone binding to the glucocorticoid receptor, glucocorticoid mediated activation of target genes, dexamethasone dependent cellular growth, with concomitant inhibition of cyclooxygenase-2 induction and inflammatory processes such as the production of prostaglandin E.sub.2. The T2 extract components triptolide and tripdiolide were effective inhibitors. The particular advantage provided by the methods herein is the treatment or prevention of inflammation and the concomitant lack of steroidal agonist effects and NSAID side effects. Conditions treatable by the present methods include inflammation and immune disorders including autoimmune disease.

Methods of Purifying and Differentiating Spermatogonial Stem Cells

The invention relates to cell proliferation, cell differentiation, male infertility, male fertility and to compositions and methods involved therein. Also methods of culturing spermatogonial stem cells with bone morphogenetic protein 8 are disclosed.

Substituted Dicinnamoylquinides and Their Use in Augmentation of Adenosine Function

A novel method of treating human diseases using natural products found in roasted coffee. The use of natural products or derivatives thereof would permit the general public to improve their health without having to use prescription drugs.

Assay for Novel Serotonin Transporter Blockers

The mutant SERTs we have developed can provide for a platform to screen for novel modes/molecules interrupting SERT function. As SERT blockers are effective antidepressants, this strategy can lead to novel antidepressant medications. It may also be useful in development of animal models to test antidepressant action in vivo.

MMP-7 Null Mice

The only MMP-7-null mouse that has been generated. Used to determine biological function of MMP-7. Mice have been used in more than 10 publications at this point, and will be distributed by a commercial vendor in the near future.

HEK-293 Cell Line Containing the Human Norepiephrine Transporter cDNA (Norepi Cell Line)

Mouse Fc-FGF-1

We produced a plasmid containing the Fc portion of mouse IgGl (Fc) coupled to human fibroblast growth factor 1 (FGF-1). The plasmid was transformed into E. coli to express the fusion protein. The fusion protein was purified on a heparin sepharose column which has high affinity for the FGF portion of the fusion protein. The purpose of making this protein was to be able to identify cells that express receptors for FGF using flow cytometry.There are multiple fluorochrome labeled antibodies to mouse IgGl. When the fusion protein is bound to FGF receptors on cells, the Fc portion is on the surface of the cells and can be detected by fluorochrome labeled antibodies to mouse IgGl. Therefore, cells that express FGF receptors and bind the fusion protein can be detected by flow cytometry or immunofluorescence.

Genetic Mutation Underlying Orthostatic Intolerence and Diagnostic, Therapeutic and Screening Methods Related Thereto

The mutation allows for the first genetic test to be conducted for one form of chronic fatigue or mitral valve prolapse which we describe as orthostatic intolerance or postural tachycardia syndrome (POTS). The technology allows for the development of this test and the development of other tests in the same gene at other loci that may contribute to similar illnesses. The awareness of a phenotype associated with the mutation in the antidepressant-sensitive NET allows for evaluation of the role of the NET gene in mental illness and thus the development of genetic tests for increased susceptibility to mental and autonomic illnesses. This is the first neurotransmitter transporter gene defect that has been shown to be linked to a disorder. The precedent act opens the door for screening for other genetic mutations in genetically related transporters such as the serotonin transporter or dopamine transporter. These latter transporters have been implicated in depression anxiety, pscyhostimulant abuse (cocaine/amphetamine) and attention-deficit disorder. Our work allows for genetic inspection of transporter genes associated with these disorders. Our work may also allow for an examination of whether circulating antibodies against the NE transporter are contributory to OI or other chronic fatigue disorders.

EP4 Transgenic Mice

mCRTH2 Expression Construct

FOXA1 as a Biomarker for Urinary Bladder Cancer

In 2009 over 70,000 American were diagnosed with urinary bladder cancer, and in that same year over 14,000 Americans died of bladder cancer. Low funding for bladder cancer helps explain the slow progress in both the identification of biomarkers and the development of new treatments for metastatic bladder cancer. Nonetheless, novel diagnostic biomarkers are needed to aid in the early identification of patients with bladder cancer, and also to determine which patients are likely to progress. Vanderbilt researchers have identified such a biomarker whose expression is reduced and lost during progression of bladder cancer.

PARS: Patient Advocate and Reporting System

Evaluation and Intervention services are supported by the Patient Advocates Reporting System (PARS). Vanderbilt University Medical Center created the Center for Patient & Professional Advocacy (CPPA) in early 2003 under the direction of Gerald B. Hickson, MD, Associate Dean for Clinical Affairs. Mission: The CPPA's mission is to promote patient and professional satisfaction with healthcare experiences and restrain escalating costs associated with patient dissatisfaction. We pursue our mission through the CPPA's inter-related functions of research, teaching, and intervention services.

Core Ordering and Reporting Enterprise System (CORES™)

CORES™ is a highly configurable, enterprise-wide software solution for research institutions. CORES™ provides full central oversight while also allowing for flexible but consistent decentralized billing and usage functionality for core facilities. This software allows core managers and customers to enter orders using a variety of methods. The software also allows customers in product cores to scan their items at a self-service checkout terminal that provides full real-time inventory management. Orders are accumulated into electronic invoices and e-mailed to customers each month. An electronic upload file containing order information is also created for the finance department. Vanderbilt has approximately 90 internal cores using this software. In addition, the software is used by several other institutions to whom the software has been licensed.

Featured Video

CTTC: Moving Innovation Forward.

To watch more videos like this one, visit CTTC's YouTube Channel.

CTTC on Twitter